Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This presentation dated 7 Feb was followed by a spike on 8 Feb.
Invasive = medical. Non-invasive = Wellness. That's a pretty positive distinction. https://fintel.io/doc/sec-nmrd-8k-nemaura-medical-2020-march-18-18339
10 to 1 makes it easy for me to calculate my losses http://ih.advfn.com/stock-market/NASDAQ/nemaura-medical-NMRD/stock-news/81282837/nemaura-medical-announces-1-for-10-reverse-split
Good points InvestDJ. The Dexcom G6 is pretty big too and that can be worn on the arm so maybe SugarBeat will find a way to prevent it being dislodged. At the moment I have put my Libre sensor on a part of my arm where it hurts when I lie on it. I put a padded strap next to it to act as a spacer. Maybe a bedtime accessory might work for SugarBeat.
All I have seen is this screen shot tweet
A hidden gem from EASD Thursday night: Nemaura Medical reveals its 24-hour wear, non-invasive sugarBEAT #CGM...CE-Marked and will launch in the UK next year. I can’t say whether it’ll do all that’s promised, but it’s certainly 10/10 on the awesome name! #EASD2019 pic.twitter.com/3M12DHSArc
— We Rate Diabetes Talks (@WeRateTalks) September 19, 2019
Good question so I just Googled and this video
This is not a product for insulin users since competing CGMs allow monitoring throughout the night and SugarBeat needs charging overnight.
Insulin users would go for a CGM with an alarm for hypos in the night. The body clock naturally makes blood sugar go low at 3:00am and night time hypos are worth avoiding.
This means that in terms of market opportunity it's not really comparable with Libre and Dexcom since those are mostly of value to Type 1s. I know Dexcom is going to reduce the price for future versions to target the Type 2 market but is will still be invasive and not as appealing as a non-invasive CGM.
SugarBeat's strength is that it is non-invasive so it could be used informally in an intermittent manner by consumers. That is likely to mean fewer repeat orders for patches but it is accessible to a large number of people even for anyone who wants to self check or self screen.
Selling with a subscription model ruins the opportunity of it being a consumer item for the health conscious so I think that's a bad idea.
Attending tonights symposium with NMRD is Dr Iain Cranston from the NHS. Here's an interesting video of him at an earlier event https://health.economictimes.indiatimes.com/news/industry/technology-is-making-people-more-aware-of-fitness-and-wellness-applications-dr-iaine-cranston/65754521
For me it puts into perspective the potential for SugarBeat if only they would sell the damn thing.
It's reasuring to see here https://www.porthosp.nhs.uk/departments/Diabetes-and-Endocrinology/d-e-consultants.htm that Dr Iain Cranson is a colleague of Partha Kar who has been a prominent influence in the encouraging funding for Freestyle Libre across regions of the NHS.
Dr. Faz Chowdhury, ...., will host a group call Wednesday, August 14, 2019 at 11 am Eastern/8 am Pacific.
To join the call, please reach Craig Brelsford, RedChip Specialist, at (407) 571-0902. Craig will give you the number of the conference line.
My suspicion is that the roll out will involve contacts in the NHS because on July 10th an NHS consultant tweeted "Good first contact with @NHSDiabetesProg from #Nemaura SugarBEAT"
@NHSDiabetesProg is: A joint initiative from @NHSEngland, @PHE_UK and @DiabetesUK working to improve outcomes for people living with diabetes and prevent Type 2 diabetes.
In a video (not sure which) Faz said that they were going to get the product out to the diabetes "community" for feedback.
The Company further reports that its UK licensee has already registered more than 17,000 expressions of interest from potential users in the UK on its website product page.
I'm having a little difficulty with that. What website? The mail form on www.SugarBEAT.com doesn't work and https://mysugarwatch.com/ is twaddle.
The European launch is a joint partnership whatever than means.
Here's a excerpt from the webinar video last September:
DG: Talk to us about your business model how you actually make money?
FC: Absolutely. So ultimately it's down to sales of the devices in various territories and the way we intend to do that is that initially we've got the UK market where where we will be launching with our licensee and then we have a joint venture partnership which is an equal joint venture adventure partnership throughout Europe and we will be launching in those territories.
In the 12 Sept 2018 webinar Faz said: By the end of this calendar year we are anticipating CE approval and launch in the UK market. Within a few months of that, so within six months from now, we anticipate launching in all the major territories in Europe and those are essentially Germany, France, Italy and Spain for example and then within 6 to 12 months we expect to launch into the Middle East and also Australia.
5 days ago a key person in the NHS tweeted: Good first contact with @NHSDiabetesProg from #Nemaura SugarBEAT
Good first contact with @NHSDiabetesProg from #Nemaura SugarBEAT
— Partha S Kar 🇮🇳🇬🇧🏏🎥 (@parthaskar) July 10, 2019
A new player enters the market of non invasive glucose monitoring?
We shall see #gbdoc @DTN_UK @JDRFUK @DiabetesUK https://t.co/dgT8llRGfB
@bigBill1 looks similar to my comment https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149622109
At 6:30 in the video he says coming months. Here's a reasonably accurate transcription:
We expect to launch the product into Europe in the coming months and the way we anticipate doing that is first of all by having a soft launch whereby we will have a product launch into various Communities and we will have individuals forming peer groups to be able to support each other in terms of the utility of the device and importantly what value they can divide derive from it because it's one thing having a device that gives you some data but it's completely different story when it comes to what do you do with that data, do you use it for therapeutic decisions, use it to motivate yourself, use it to for lifestyle adjustments for example.
I would not expect a commercial product launch announcement for some months. Sounds like they have little clue how to market it.
Amazon is very popular in the UK and they sell Libre. https://www.amazon.co.uk/Freestyle-Libre-Sensor-Pack-2/dp/B01BUANEDS
Looking at the chart that shows volume on https://uk.finance.yahoo.com/quote/NMRD?p=NMRD (click the chart and zoom in) I noticed frequent net purchase volumes in the morning of 100 shares every few minutes, increasing to 200 in afternoon like a low profile buying program. That's why there are so many transactions.
Would that tickle the market maker algorithms into increasing the SP? It's very close to the $1 threshold now. Yahoo page shows only 77k volume for 9.8% SP increase.
Also I see that in the last few days the Ascendiant buy recommendation is showing on that Yahoo page so that's a good sign. That could provided a trigger to get the news out.
Good point. My Freestyle Libre is a reader only but I voluntarily upload by plugging into a computer via USB. That's a bit cumbersome to do with a watch.
(Libre does have an option to use a phone app directly provided the mobile has near field communication so it can be held against the sensor so a minority of users would have that).
@BigBill1 I'm indulging in unfounded optimism in assuming the website doesn't show a watch because it's a closely guarded secret. Yeah you're probably right.
@iddrisw After slagging off the name MySugarWatch it occurred to me that the standalone reader could be a watch format then the name would make sense. Perfect sense.
https://www.google.com/search?q=site:mysugarwatch.com show the pages on their site that Google has indexed. One page is titled dcr, Author at mySugarWatch so maybe the website creator's initial are drc.
Allowing all those old pages to continue to exist but each resolving to the same content is going to be treated by Google as duplicated content and the site penalised. Just in case NMRD are reading this! Ho Ho.
MySugarWatch is such an incredibly stupid name because Watch is clearly ambiguous and any marketing novice will know that confusing the customer is disastrous.
I'm therefore a bit worried that MySugarWatch.com was updated rather than deleted. If DBE knew what they were doing they would know that a website with a form on it to collect email addresses that actually does nothing because there is no code behind it is going to annoy interested people.
Yes the website is definitely controlled by an amateur.
https://www.ascendiant.com/Services/Equity-Research/Research-Reports Report is available as a pdf after you enter your email address.
When is a watch not a watch? When it is mySugarWatch. A stupid name that will cause confusion.
@think4yourself At the moment the price is up 5.41% on volume of only 1,712. I have noticed that three successive periods of small net purchases has moved the price substantially in the recent past so if getting above $1 was important it wouldn't take much to do it.
Just for interest I Googled "dexcom g6 insertion needle" and looked at Google Images. You can see a horrendously long needle for the G5 sensor. I think the current G6 is much the same but the insertion device looks much nicer.
The Freestyle Libre needle looks much shorter but is still enough to make millions of Type 2's refuse to use it. Type 1's are pretty used to stabbing themselves but it's bound to be an ordeal for some.
This is one reason why non-invasive is something worth getting excited about.
Just to add context to the watch idea, Apple's interest in Glucose monitoring is to sell watches which are pretty expensive and therefore of no interest to a big section of the diabetes community. It's therefore interesting but not a game changer.
For example I'm not going to buy an Apple Watch because I need to monitor my blood glucose. If I was in the market of buying a smart watch the glucose feature would definitely be a boon though.
So basically adding a health feature to a high price product does not change the game for the lower cost dedicated product market.
A tie-up between Decom and Apple makes great branding for Dexcom so that's good for their overall marketing and sales.
InvestDJ I wouldn't be surprised if Eversense goes bust in the next 5 years. I don't want a surgical procedure twice per year to replace 26 simple but sometimes unpleasant Libre applications and I cannot imagine many others wanting that either. It could have a tiny niche use say for althetes who swim but otherwise I doubt it will ever catch on.
The clincher in the UK at least it that the job of removing the old sensor and inserting the new one requires surgical skills that are expensive and in short supply. I can't see the UK NHS going for it whilst there are alternatives like Libre and SugarBEAT.
When I think about it I cannot actually believe the invention exists. From my perspective it seems pretty stupid.
@iddrisw Yes I often feel tethered to my Libre and sometimes the demand to monitor can feel like enslavement. No I don't think intermittent monitoring is any good for me or anyone else on insulin.
Today I was driving in the Portugal heat and simply popped a sweet in my mouth when my blood sugar began to fall after lunch had driven it up. Without monitoring life would be a real pain in the arse.
It would be a different story for Type 2s on tablets which don't drive your blood sugar down. It would be useful for them to use intermittent to help them learn to modify their behaviour and that could reduce the financial burden on the health service long term since the complications that come later are very expensive. There's a huge number of T2s struggling in the dark.
T2s with drugs that stimulate the pancreas to lower blood sugar can get dangerous hypos. There's a case for them to have a 24/7 monitor but intermittent use allows a provider to spread the cost between patients.
I agree but I have a feeling nmrd might be reviewing the situation. It's fashionable in the tech industry to rave about disruptive technology. Maybe $2 is a bit too disruptive to begin with especially for a minow company. Maybe they think it's better to be similar in price to Libre to begin with for a gentle lead in. Big competitors have the abillity to lower their price if they have to but nobody wants to rock the boat, just yet.
I have often been a put off by the cheesy tip sheet feel of Red Chip. Say wonderful things and the share price goes down. I hope they engage a profession marketing company to get things rolling.
Maybe do both with a discount for subscribers. Then there is no pay-wall for casual users. Gathering data is useful for development but I doubt if the healthcare back-up idea will come to much though it looks impressive from a marketing point of view.
The gathered data will be pretty chaotic and noisy and I wouldn't expect users to enter details of behavior into the app. I have that facility on Libre and life is too short to bother with entering meal sizes etc.
@iddrisw thanks for all your input and research here. I've been lurking on the conversation.
I have adult onset Type 1 which is called LADA (latent autoimmune diabetes of adulthood). The pertinent feature of this is that I was originally diagnosed and treated as type 2 and I took a range of T2 drugs and finger pricked once per day. I actually start measuring by peeing on Diastix. So I can say that I have been T2 and well as T1.
Looking back to "when" I was T2 I would have absolutely loved to have a 24/7 monitor since the medication is a blunt instrument that sends you drifting in one direction and a speed you cannot see. Usually the medication is insufficient to prevent a meal sending your blood sugar too high and you get a very depressing shock when you measure after a meal. At other times you get a hypo which comes from nowhere since it is normal not to take note of the carbohydrate content of your meal. As T2 you aren't told to do that. So as T2 life is depressingly haphazard.
Another feature of T2 is that since the feedback information is so poor it is easy to turn a blind eye to the illness. That's the deadly and costly thing about Ts. I have seen a T2 who measures once per day make the decision to eat dessert with the attitude "well I guess it's ok". With the feedback a CGM would provide that T2 would have a massive incentive to make a beneficial decision to just say no to that dessert.
When Nmrd suggested T2 would be a target customer base that's what clinched it for me. However price is critical. I see a difficulty because I believe NHS budgets for T1 is higher per patient than for T2 because insulin is more precise and effective and also dangerous when mistakes are made. It is like T1 is sharp whilst T2 is blunt. The number of T2s is massive compared with T1s. I don't think the NHS has the funds to dish out CGMs to all T2s. Since SugarBEAT has the flexibility of daily use the product can be useful for T2 on an intermittent basis and at a lower cost. T2s will want it 24/7 but there's not the funding yet there's a way that the NHS can feasibly use it on a kind of rationed basis. You can't be intermittent with Dexcom or Abbott Libre.
Luckily the intermittent use feature allows NMRD to hover alongside Dexcom and Libre rather than be in battle with them so although those competitors will be irked they shouldn't feel threatened. Dexcom aims to get cheaper with their collaboration with Google's Verity and target T2 and Libre is already making inroads into T2 but that would have to be for a small percentage of T2 patients deemed to benefit from the expenditure.
T1 is very different to T2 in terms of management. You look at the meal and estimate the carb, choose your insulin dose and eat. You do this for every meal. Insulin last 4.5 hours but the effect of the carb in the meal lasts a lot less and the time depends on the type of carb. To stop your blood sugar going too high you have to take so much insulin that you simply know that in 3 hours time you will go dangerously low and therefore are compelled to eat some carb. That is my experience. The point is T1 is much more predicatable and supposedly more manageable that T2. The trouble is that when the carb in the food runs out and the insulin continues working and drives you into the danger zone you happen to be busy doing something interesting like living a normal live and not being obsessed with diabetes. A CGM alarm that you can program for your own situation is a godsend.
I hope that helps with undestanding the practicality differences between T1 and T2 and what GCM means for both.
There is a contradiction between the claim of SugarBEAT being flexible and the subscription model which is inflexible. We shall see how that pans out. You can't tell me I have the freedom choose when I use the product in one breath and force me to buy a certain quantity at the same time. That's not good marketing.
I'm not keen on the subscription model. T1s might make the commitment but T2s, prediabetics and health conscious would surely prefer an informal financial commitment.
Faz is a great scientist but a poor salesman. He tries to say SugarBEAT is cheaper than Libre by comparing 16 days SugarBEAT use with 28 Libre use. If you have a high margin the most flexible tool at your disposal is a price adjustment. On the other hand undercuttin too much starts a race to the bottom that benefits nobody.
Faz is a great scientist who has invented something potentially incredible for the diabetes community but from his language in his videos, as a potential end user I can tell he does not have a depth knowledge of diabetes that customers need to hear. That used to worry me a bit. I was relieved when Dr Fred joined the team.
Fair point!
Thanks @BigBill1. You mentioned exercising but not exercising+selling so I wonder if you meant something else. As I said to Jaguarjacket its a crap time to be doing that.
I would have thought those warrant holders would have a bit more nounce. They could have make a lot more a few weeks ago - maybe they did and are program selling without a care for optimising profit.